GAMMA Investing
CRDF icon

GAMMA Investing’s Cardiff Oncology CRDF Stock Holding History

GAMMA Investing’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-147
Closed -$191 – 4343
2026
Q2 		$191 Sell
147
-1,082
-88% -$1.72K ﹤0.01% 4096
2026
Q1 		$1.99K Buy
1,229
+483
+65% +$992 ﹤0.01% 3669
2025
Q4 		$2.1K Buy
+746
New +$1.73K ﹤0.01% 3586

Other funds holding CRDF

GoalVest Advisory
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Post Resch Tallon Group
Post Resch Tallon Group Pittsford, New York $146M AUM 18.19% 1-Year Est. Return
Baker Ellis Asset Management
Baker Ellis Asset Management Vancouver, Washington $917M AUM 26.82% 1-Year Est. Return
Capital Advisors Wealth Management
Capital Advisors Wealth Management Yakima, Washington $888M AUM 16.06% 1-Year Est. Return
Ledgewood Wealth Advisors
Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

GAMMA Investing's CRDF Position: Q3 2026 in Review

GAMMA Investing sold out of Cardiff Oncology (CRDF) in Q3 2026, closing a stake of 147 shares — an estimated $191 sold.

GAMMA Investing first reported a position in CRDF in Q4 2025 and held it in 3 quarters. The position peaked at $2.1K in Q4 2025. 12 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.

  • GAMMA Investing reported no remaining Cardiff Oncology position as of Q3 2026 after selling out during the quarter.
  • GAMMA Investing sold 147 Cardiff Oncology shares in Q3 2026, an estimated $191.
  • GAMMA Investing first reported a position in Cardiff Oncology in Q4 2025 and held it in 3 quarters.
  • GAMMA Investing's Cardiff Oncology position peaked at $2.1K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.